Navigating the Multi-Dimensional Complexity of Drug Pricing Policies

Dr. George Poste
Chief Scientist, Complex Adaptive Systems Initiative and Regents Professor of Health Innovation
Arizona State University
george.poste@asu.edu
www.casi.asu.edu

NASEM Affordable Drugs Stakeholder Meeting
23 January 2017
Stanford Law School
US Prescription Drug Market Trends

- CAGR of 1.8% 2005-2013
- dramatic 11.5% expansion in 2014
  - HCV, MS, diabetes Rx innovations
- increased tension between innovators and buyers
  - strengthening of innovation pipeline (immuno-oncology)
  - buyer consolidations: PBMs, wholesalers, insurers
- lower rate of patent expirations and fewer generic market entries (except biosimilars/follow-on biologics?)
Speciality Drugs

- $87.1 billion in 2012
- est. $192 billion in 2016
- projected $401 billion in 2020
- 20% CAGR
- higher impact on patient OOP spend/deductibles than traditional lower cost small molecular weight drugs
Waiting In The Wings

- new orphan drugs and gene therapy
- immuno-oncology combination Rx
  - CTL4 + PD1-PDL1 inhibitors
  - $300,000 per treatment (before cost of clinical services)
- immuno-oncology cell therapies
  - individualized TIL, TCR, CAR therapies
  - estimated $0.5 to 2 million/patient
Unmet Medical Needs and Disease Burden: Confronting the Largest Economic Disruptions to Achieve Sustainable Healthcare
“I’m glad to call the pharmaceutical industry one of my biggest enemies.”
Campaign speech August 2016

“The (biopharmaceutical) companies are getting away with murder.”
Tweet 11 January 2016
Uni-dimensional Analysis of Complex, Multi-Dimensional, Multi-Component Systems

A Prescription for Flawed Conclusions, Ineffective Reforms and Unintended Consequences
Unidimensional Approaches to Complex, Multidimensional Problems: A Prescription for Flawed Conclusions, Ineffective Reforms and Unintended Consequences
The Innovator Industry Perspective
Industry Perspectives and Concerns
High Risk – High Cost R&D

• highest % sales reinvested in R&D in any industrial sector

• 10-15 year R&D cycle: varied estimates of $1B to 2.6B per drug

• escalation of R&D cost without parallel gains in new product launches

• high attrition rates in clinical trials including advanced Phase III trials

• precision medicine and stratification of major diseases into smaller cohorts

• increased requirements to demonstrate post-approval clinical effectiveness (real world evidence)
• declining ROI on R&D investment
Industry Critics

- lack of transparency in claimed $1 to 2.5 billion R&D cost per product
- US subsidizes other countries with prices 1.5 to 3X higher than EU
- “pay-for-delay” and “product hopping” arrangements to slow entry of generic competition for branded Rx
- over-investment in lower risk “me-too” product classes versus high risk, transformative innovation
Ongoing Clinical Trials with New Cancer Immunotherapies

“I have never seen this before, where you have so much development activity in the same class of drugs.

Should these resources, I’m not only talking about financial resources but also patient resources, be better off spent into looking at more novel drugs.”

Dr. R. Pazdur,
Acting Director, FDA Oncology Center of Excellence
Cited in Cancer Letter 7 October 2016, p.4

- 803 registered trials with 20 investigational agents (11/16)
  - single agents
  - combinations with other immunotherapies, biologics, chemotherapy and vaccines
A Very Expensive DTC Campaign

First FDA Approved Immunotherapy for previously treated advanced stage lung cancer. Half the OPDIVO patients were alive at 9.2 months versus 6 months for chemotherapy (docetaxel).

Most Prescribed Immunotherapy For Previously Treated Advanced NSCLC. In a clinical trial of squamous patients, half of those on OPDIVO were alive at 12.2 months versus 9.4 months for chemotherapy (docetaxel).
Completely Different Animals Or All Part of the Same Rapacious Industry to Critics of Drug Prices?

R&D Intensive Innovator Companies

Zero R&D, Asset Stripping and Extravagant Price Increases in Off Patent Single Source/Limited Competition Markers

Martin Shkreli
Turing Pharmaceuticals

Michael Pearson
Valeant Pharmaceuticals

Heather Bresch
Mylan
“Many of the same companies that are discovering and developing innovative drugs are also gouging the market, hiking up prices 400 to 500%, year after year, on old drugs, particularly off-patent biologics. This is the industry’s dirty little secret. Shkreli’s crime was attracting the spotlight to the shadows.”

Editorial: An Unusual Business
Nature Biotechnology (2015) 33, 1113
Biopharmaceutical Pricing: “What the Market Will Bear”

- What “the market will bear” in treatment categories with only one or two branded products
- Entry of new competitor products with minimally different properties results in price increases for all
- Major price reductions do not occur until LOE and entry of generic Rx
  - Rate of generic price decrease influenced by number of competitors
- Uncertain impact of biosimilars/follow-on biologics in markets with only one or two entries
The Vicious Cycle in Pharmaceutical Pricing

Increased Prices → innovator and generic companies

- increased co-pay cards offset patient cost but impact margin

innovator and generic companies → formulary restrictions and increased rebates

- fulfill shareholder growth expectations in face of offsets

formulary restrictions and increased rebates → PBMs Insurers

- vehicles to reduce drug use and cost

PBMs Insurers → increased cost burden

- reduce risk by cost shifting via increased OOPs, deductibles

increased cost burden → patients

- increased cost burden

patients → governments and employers

- offset patient cost but impact margin

governments and employers → increased cost burden

- fulfill shareholder growth expectations in face of offsets

increased cost burden → Increased Prices
Biopharmaceutical Pricing

- Innovator net margins have remained largely constant despite escalating invoiced prices
- Lack of transparency about how the remainder of the expanded margin is divided - who receives discounts, rebates, co-pay subsidies?
- Opacity in the scale and trajectory of Rx company margin offsets paid to different stakeholders - PBMs, payers, insurers, patients?
The Crazy World of Rebates and Subsidies in the Gross to Net Pricing of Branded Pharmaceuticals

- differential (discriminatory) pricing
- payer channels
  - Medicare Part D, Medicaid, DOD, VA, Employer Group Waiver Plans
- therapeutic class
  - HIV, hepatitis C, insulin, ICS/LABA,
  - speciality biologicals, immuno-oncology (I/O)
- disease categories and patient co-pay cards
  - acute, chronic
- disease co-morbidities
  - polypharmacy and bundled care
- Rx life cycle
  - launch, mature, post-LOE (generic)
“The American public and our government need to see what’s going on…. it’s necessary that the entire (pricing) system come clean.”

Ron Cohen
Chairman, Biotechnology Innovation (BIO)
Executive Board
Congressional Testimony
September 2016
The Information Gap

“We don’t have enough public information on the effectiveness of new drugs in the real world or about prices and rebate structures. We must increase the transparency of the information available about drug pricing and value.”

Andy Slavitt
Acting Administrator, CMS
HHS Forum on Drug Prices, 20 November 2015
Cited in Scrip 4 Dec. 2015 p.11
Control of Drug Expenditures by Health Plans

- multi-tier formularies
- higher deductibles and co-pays for high-tier drugs
- ‘split-fill’ for initial Rx regimen to limit waste from stopping due to AEs
- increased prior authorization
- ‘step therapy’: treatment with lower cost drug(s) before approval of more expensive Rx
- ‘clinical pathways’: physician (dis)incentives to adopt consistent Rx use
ACA and Growth of Multi-Tier Formularies in Health Exchange Plans

- ‘closed’ formularies
- only cover a fraction of speciality drugs
- consumers carry full cost for Rx not on formulary
- high deductibles and large co-pays
Pharmaceutical Industry Discount Coupons/Cards 2015*

- estimated $7 billion in 2015 versus $1 billion in 2010 (IMS Holdings)
- PBM actions to exclude Rx with coupons from formulary
  - Express Scripts 80 drugs
  - CVS/Caremark 120 drugs
  - UnitedHealth Group 35 speciality drugs
- 62% coupons are for Rx with low cost alternatives

The Perversity of Site of Service and 340B Abuses on Profit Margins for Administration of Cancer Drugs

- UHC
  - independent community oncology clinics ASP + 28%
  - hospital-owned cancer clinics ASP + 152%
- ‘seduction by margin’ exacerbated by 340B pricing
  - heavily discounted (30-50%) drugs prescribed to fully insured patients
  - makes use of high cost drugs irresistible
- incentive for hospitals to acquire independent practices and reclassify as 340B eligible hospital outpatient settings
Recommendation

- prohibit sale of 340B highly discounted products at higher prices other than to low income/indigent populations consistent with intent of original 1992 provision
- repeal state provisions that allow mandatory reimbursement for physician selected anti-cancer drugs irrespective of clinical benefit or guideline compliance
Recommendation

- allow Medicare to negotiate improved pricing on brand-name drugs
- require transparency on prices and margins for multiple stakeholder transactions beyond just Rx companies - PBMs, pharmacies, providers
- deny tax breaks for DTC prescription drug advertising
Recommendation

- convert permissive generic substitution polices to mandatory
- eliminate patient consent requirements for generic substitution
- limit ‘carve outs’ for substitution in particular disease categories
- strengthen FDA resources for generic drug review/approval
“Price is what you pay. Value is what you want.”

Warren Buffet
Value-Based Pricing Models

- bundled payment models
- performance (outcome)-based risk sharing
- indication-specific pricing
- annuity model
- reference pricing
- essential social goods and public utility model
Performance-Based, Risk Sharing Contracts

- Januvia (sitagliptin)/Janumet (plus metformin)
  - reduction in HbA1C levels in T2 diabetes

- Rebif (interferon Beta-1a)
  - reduction in ER visits/hospitalization in MS patients

- Harvoni (sofosbuvir/ledipasvir)
  - elimination of HCV genotype 1 in carriers

- Crestor (rosuvastatin)
  - LDL cholesterol reduction
Outcomes-Based Pricing: More Complicated Than It Might Seem

- consensus on clinical and/or molecular biomarker metrics as efficacy/effectiveness endpoint(s)
- consensus on ‘observational/PCT’ protocols to be used
  - duration and data collection parameters
- mechanisms to encourage/enforce protocol compliance and ID protocol deviations
Outcomes-Based Pricing

- acute diseases versus chronic diseases
- chronic diseases with uni-focal Rx target (e.g., HCV) versus chronic diseases with complex multi-focal perturbations in complex molecular networks (e.g., cancer, neurodegeneration)
- monotherapy versus polypharmacy protocols (multiple comorbidities)
# Hypothetical Scenarios for Indication-Based Drug Pricing

<table>
<thead>
<tr>
<th>Drug and Indication</th>
<th>Median Survival Gain In Years</th>
<th>Current Monthly Price</th>
<th>Price Based On Indication With Most Value</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Abraxane (Celgene)</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Metastatic breast cancer</td>
<td>0.18</td>
<td>$6,255</td>
<td>$6,255</td>
</tr>
<tr>
<td>Non-small cell lung cancer</td>
<td>0.08</td>
<td>$7,217</td>
<td>$2,622</td>
</tr>
<tr>
<td>Pancreatic cancer</td>
<td>0.15</td>
<td>$6,766</td>
<td>$448</td>
</tr>
<tr>
<td><strong>Tarceva (Roche/Astellas)</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>First-line treatment metastatic non-</td>
<td>0.28</td>
<td>$6,292</td>
<td>$6,292</td>
</tr>
<tr>
<td>small cell lung cancer</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Pancreatic cancer</td>
<td>0.03</td>
<td>$5,563</td>
<td>$1,556</td>
</tr>
<tr>
<td><strong>Erbitux (BMS/Lilly)</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Locally advanced squamous cell</td>
<td>1.64</td>
<td>$10,319</td>
<td>$10,319</td>
</tr>
<tr>
<td>carcinoma of head/neck</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>First-line treatment recurrent or</td>
<td>0.23</td>
<td>$10,319</td>
<td>$471</td>
</tr>
<tr>
<td>metastatic squamous cell carcinoma</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>of head/neck</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Herceptin (Roche)</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Adjuvant treatment breast cancer</td>
<td>1.99</td>
<td>$5,412</td>
<td>$5,412</td>
</tr>
<tr>
<td>Metastatic breast cancer</td>
<td>0.40</td>
<td>$5,412</td>
<td>$905</td>
</tr>
</tbody>
</table>

*Source: JAMA article by Peter Bach, Oct. 3, 2014*
Value-Based Frameworks for Drug Pricing

- no consensus about evaluation criteria and weightings
- composite from “scores” to “scales” to traditional QALYs
- QALYs do not assess how to weight AEs or ancillary patient-caregiving Ux benefits
- evaluation of individual therapies does not address overall budget impact
  - sofosbuvir for HCV has acceptable QALY but large patient volume creates aggregate cost that overwhels budgets
Reference Pricing

- uniform pricing of Rx deemed “clinically comparable”
- how should “clinically comparable” be defined?
- instructive precedents?
  - demise of antibiotic R&D
  - immuno-oncology drugs with apparent common MOA but different efficacy (Opdivo™ vs Keytrada™ in NSCLC)
Drug Pricing in Europe

- one country uses price of Rx in a basket of countries to derive benchmark/reference price
- erratic variation in size/composition of basket for comparison
- formulaic variation
  - branded products only vs brands + generics
  - average of lowest prices or lowest price in the basket
- impact of currency variation and distortion of parallel importing
- Rx shortages in countries with low prices
## Interventions With Potential for Curative Outcomes

<table>
<thead>
<tr>
<th>Criteria</th>
<th>Gene Therapy</th>
<th>Stem Cells</th>
<th>TIL, TCR CAR</th>
<th>Organ Transplant</th>
<th>Implantable Devices</th>
</tr>
</thead>
<tbody>
<tr>
<td>one-time procedure</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
</tr>
<tr>
<td>major upfront cost</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
</tr>
<tr>
<td>high R&amp;D complexity</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>N/A</td>
<td>✓</td>
</tr>
<tr>
<td>clinical complexity</td>
<td>L – M</td>
<td>L – M</td>
<td>H</td>
<td>L – M</td>
<td>L – M</td>
</tr>
<tr>
<td>life changing potential</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
</tr>
</tbody>
</table>

- pricing claims based on ‘one time’ efficacy and elimination of accrued cost of multi-year care (multi-modalities)
- proposals for capped annuity schemes to spread cost over multiple years and limit risk of efficacy not maintained
- requires facile mechanism for annuity transfer between health plans
- potential for discriminatory transfer rejection by new plans or self-funded employer insurance
The Cost of Cancer (USA)

- average price of new cancer drugs has increased 5-10 fold over past 15 years.
- trends in insurance coverage for OOP co-payments by patients has increased to 20-30% drug cost
- average annual US household gross income is $52K and $24.1K for Medicare beneficiaries
- US cancer patients more than twice as likely to declare bankruptcy versus other chronic diseases
Cancer Exceptionalism: No Limits-Clinical or Economic?

What Represents a Meaningful Advance in Clinical Effectiveness?

Are Regulatory Approval Hurdles Too Low and ‘Breakthrough’ Status Being Granted Too Frequently?

Is There a Price Point That is Unacceptable Regardless of Long Term Value?
Gains in Progression-Free Survival (PFS) and Overall Survival (OS) for 71 Drugs Approved by the FDA From 2002 to 2014 for Metastatic and/or Advanced and/or Refractory Solid Tumors

From: T. Fojo et al. (2014) JAMA Otolaryngology–Head & Neck Surgery 140, 1225
Futile Therapy in End-of-Life Care Recommendation

- require providers to absorb cost of administration of futile Rx last two weeks of life in patients with advanced chronic diseases other than for symptom palliation and comfort
  - confronting the ‘hang the chemo-bag’ or start a new chemo-regimen for cancer patients in ICU or hospice care and deteriorated performance status
  - pharmacy data on prevalence and providers
The Promise of Immunotherapy
The Promise of Immunotherapy: Is Widespread Adoption Economically Feasible?

- unit Rx cost (> $100K)
- indirect care cost
- escalating cost of combination Rx regimens (> $200K)
- extravagant cost of cell-based therapies ($500K - $1.5 million)
- complex clinical management challenges and compatibility with community oncology services

40-80% patients fail to respond even with I/O – I/O combinations
R&D Costs Continue To Increase In An Increasingly Cost-Sensitive Market

The Imperative to Improve the Efficiency of the R&D Process

Precision Medicine and Implications for Biopharmaceutical R&D and Pricing
Factors Influencing Growth in Clinical Trial Costs

- increased complexity
  - data points per patient
- wide variation in IRB performance
  - delays and overall trial extension
  - institution-specific protocol revisions
- cost of clinical site setup costs and training
- high dropout rate of recruited centers
- patient recruitment and retention
- increased use of comparator trial aims to address payer requirements for RWE
Streamlining Clinical Development

- implement cost reduction process efficiencies
  - use of centralized IRBs versus multiple institutional IRBs
  - new analytics for faster remote data entry and uploading to EHRs
  - increased use of remote health status monitoring, protocol adherence and patient-reported outcomes
Streamlining Clinical Development to Reduce Cost and Accelerated Access for Patients

Recommendation

- allow post-registration, pre-approval communication with payers to accelerate formulary placement and reimbursement negotiations
Biopharmaceutical Innovation: The Need to Improve R&D Efficiency

- reluctance to use molecular profiling to segment patient cohorts to differentiate Rx responder and non-responder subsets
  - Companion (CoDx) and complementary (CmpDx) diagnostics
  - market fragmentation versus traditional one-size-fits-all Rx regimen(s)
  - labeling restrictions to limit Rx to CDx-identified responder subpopulation(s)
Population-Based Payment Models

- “one-size-fits all” Rx regimens
- treating both responder and non-responder cohorts distorts cost-effectiveness calculus
- additional cost of adverse events from inappropriate exposure of non-responder cohorts to futile Rx
Precision Medicine and Drug Pricing: Confronting the Non-Responder Problem

Industry Risk
- criticism and harsh spotlight on high cost Rx with high non-responder fraction
- futile therapy
- AE risk and cost

Industry Opportunity
- robust predictive identification of responder (R) and non-responder (NR) patients
- premium pricing and risk sharing
- improved outcomes
- cost savings by elimination of futile Rx/AE risk

oncology drugs as demonstration platform
Confronting the Non-Responder Problem

Industry Risk
- criticism and harsh spotlight on high cost Rx with high non-responder fraction
- futile therapy
- AE risk and cost

Industry Opportunity
- Robust predictive identification of responder (R) and non-responder (NR) patients
- Premium pricing and risk sharing
- Improved outcomes
- Cost savings by elimination of futile Rx/AE risk

Oncology drugs as demonstration platform

The Single Greatest Opportunity for Industry Innovation and Cost Effective Rx Use?
The Path to Precision Medicine: From Superstitions to Symptoms to Subtype Signatures
Precision Medicine: Molecular Subtypes, Endophenotypes and the Dynamic Range of Clinical Phenotypes

Symptom and Organ-Based Disease-Based Classification

D1 | D2 | D3 | Oncology

Molecular Subtypes and Prevalence

CNS | Autoimmunity | CV/Metab

Shared Network Perturbations in Different Diseases

early | late

Oncology
Challenges in the Use of Molecular panOmics Profiling to Identify Rx Responder (R) and Non-Responder (NR) Patients

- market fragmentation into R and NR subsets as disincentives to Rx companies without guaranteed premium pricing for performance-based outcomes in R subset(s)
- current public and private sector reimbursement policies as major obstacle to develop R-NR profiling assays
A Pricing and Reimbursement Dichotomy

Dx

Rx
Challenges in the Use of Molecular Profiling to Identify Rx Responder (R) and Non-Responder (NR) Patients

- anachronistic reimbursement policies for CoDx/CmpDx assay development

- traditional unianalyte LDTs @ <$100 and low development cost (<$5MM)

- new complex multianalyte panOmics platforms for CoDx/CmpDx validation requires larger sunk R&D cost, clinical trials and regulatory validation - $100-300 million

- current reimbursement policies as existential threat to emerging molecular diagnostic industry and delayed trajectory for precision medicine
Development of Diagnostic Assays to ID Rx Responder (R) and Non-Responder (NR)

- Incentivize Rx industry to develop diagnostics to differentiate R and NR cohorts
  - premium pricing and labeling constraints for use in R patients only

- Overcome current industry reluctance to invest by imposition of progressive price reduction over five years post-launch until R-NR assay introduced
  - reduction amortized over five years based on projected cost of futile Rx in documented percentage of NR patients
Recommendation

- establish reimbursement policies for products and services that improve medication adherence
  - innovator companies, providers
  - telemedicine, wearables
  - use of digital assistants
  - patient coaching and education tools
  - provider alerting systems of non-adherence patterns that pose serious clinical risk
Society must seize control of the antibiotics crisis

Pressure from the public could force firms to develop new drugs that treat resistant infections, says Carlos Amábile-Cuevas.

Biomedical Products As a Public Good

Proposals for Adoption of a ‘Public Utility’ Model for ‘Essential’ Biomedical Assets
The Public Utility Model for Essential Public Goods Products

- water, electricity, gas, critical infrastructure
- regulated pricing plus periodic price increases
  - inflation
  - infrastructure depreciation and new investments
  - R&D investment in new technological alternatives for supply chain improvements and/or consumer benefit
Alternative Models for Increased Public Sector Engagement in Biopharmaceutical Development

- current non-biomedical adoption involves known commodity products
- unclear how R&D risks (failure) would be translated to ‘final price’
Alternative Models for Increased Public Sector Investment in Biopharmaceutical Development

- independent public sector network for conduct of clinical trials and product registration
  - more transparent cost?
  - superior process efficiency?
  - poor performance of AMCs, NCATs, NCCN as benchmark precedents?

- GoCo model
  - which elements of discovery, development and registration?
  - manufacturing only?
  - poor performance of NIH in CBW countermeasure translation/development (Bioshield) as benchmark?
“Double Dipping”

“Taxpayers who helped fund drug development find themselves unable to afford the cost of treatment.”

Rep. Jan Schakowsky (D.IL)

“These (biopharmaceutical) companies grow their businesses with the benefit of taxpayer-sponsored research and then they turn around to gouge the same taxpayers without whom the drug may not even exist.”

Rep. Rosa DeLauro (D.CT)

The Affordable Drug Pricing Task Force (Democrats Only)
How to Identify and Quantify the Contributions of Taxpayer-Funded Research to Commercial Products

- intellectual lineages of conceptual or technological advances are diffuse and diverse
  - how to demarcate who funded what, when and who?

- contemporary academic biomedical research is increasingly dependent on innovations originating in industry

- reciprocal industry entitlement to recoup investments based on public funded research that cannot be reproduced?
Why Focus on Pharmaceutical R&D as a Beneficiary of Taxpayer-Funded Research and Exclude Other Industrial Sector Beneficiaries?

Telcoms | GPS | Computing | Internet | Social Media
---|---|---|---|---
Novel Materials | Geophysics | Robotics | 3D printing | Biotechnology
The Healthcare Challenge: Sustaining Innovation, Improving Outcomes and Reducing Cost

- Unmet Medical Needs
- Access to Affordable Care
- Infinite demand versus finite resources
- Improved Outcomes: clinical, economic, quality-of-life
- Continuity in care
HELL IS THE PLACE WHERE NOTHING CONNECTS — T.S. ELIOT
WELCOME TO THE MULTI-DIMENSIONAL OPAQUE MATRIX OF HEALTHCARE PRICING
● the sale and pricing of biopharmaceuticals (and much else in healthcare) do not confirm to free market principles

● the pricing of drugs and all aspects of healthcare financing are shaped by myriad sectorial inefficiencies and perverse information asymmetries that render the true costs and profit distribution opaque across the entire supply chain
The Elusive Core Components in the Drug Pricing Debate

- transparency in diverse transactional components in the Rx supply chain
- consensus on what constitutes value in Rx use
- addressing drug pricing as a complex multi-dimensional problem versus a simplistic, unidimensional focus on list prices
- sophisticated analysis of how Rx selection and use patterns affect the effectiveness and cost of other components of the healthcare ecosystem
“For Every Complex Problem There Is an Answer That is Clear, Simple and Wrong.”

- H.L. Mencken